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Abstract
Even if the overall survival of children with
cancer  is  significantly  improved  over  these
decades, the cure rate of high-risk pediatric
solid tumors such as neuroblastoma, Ewing’s
sarcoma family tumors or rhabdomiosarcoma
remain challenging. Autologous hematopoietic
stem  cell  transplantation  (HSCT)  allows
chemotherapy  dose  intensification  beyond
marrow  tolerance  and  has  become  a  funda-
mental  tool  in  the  multimodal  therapeutical
approach of these patients. Anyway this proce-
dure does not allow to these children an event-
free survival approaching more than 50% at 5
years. New concepts of allogeneic HSCT and in
particular HLA-mismatched HSCT for high risk
solid  tumors  do  not  rely  on  escalation  of
chemo  therapy intensity and tumor load reduc-
tion but rather on a graft-versus-tumor effect.
We here report an experimental study design
of HLA-mismatched HSCT for the treatment of
pediatric solid tumors and the inherent prelim-
inary results.
Since the 1950s, the overall survival of chil-
dren with cancer has gone from almost zero to
approaching 80%.1-5 Although there have been
notable  successes  in  treating  solid  tumors
such as Wilms’ tumor, some childhood solid tu-
mors  have  continued  to  elude  effective
therapy.  In  particular,  the  real  challenge  re-
mains the cure rate of the high risk pediatric
solid tumors such as the listed below: i) neu-
roblastoma  (NB):  stage  IV  disease  or  other
stage with n-myc amplification, resistant or re-
lapsed disease after conventional therapy; ii)
Ewing’s family tumors (ESFT): stage IV dis-
ease  or  localized  tumors  with  <  80%  of
necrosis after neo-adiuvant therapy, resistant
or relapsed disease after conventional therapy;
iii) rhabdomiosarcoma (RMS): metastatic dis-
ease or alveolar histology, resistant or relapsed
disease after conventional therapy.
With the use of high dose chemotherapy fol-
lowed  by  peripheral  hematopoietic  stem  cell
(HSC)  rescue,  dose  escalation  has  been
pushed to the edge of dose-limiting toxicities.
The examples of NB7 and ESFT5,8 in this sense,
are paradigmatic. Despite the development of
new treatment options, the prognosis of high-
risk neuroblastoma patients remains dismal; in
more than half of patients the disease returns.
High-dose  chemotherapy  and  haematopoietic
stem cell rescue, might improve the survival of
these patients but the actual 5-years EFS is not
yet over 30%. High risk ESFT and RMS as well,
have not achieved over these two decades a sig-
nificant better EFS after a wide use of autolo-
gous HSCT, being the 5-year EFS respectively of
51%7and 20%.3 Nowadays, is clear that any fur-
ther improvements in EFS of these high risk tu-
mors have to be achieved through novel thera-
peutical approaches. Interest in new therapeu-
tical tools has been renewed at the beginning
of this century with the first successful reports
of reduced intensity conditioning (RIC) trans-
plants in solid tumors, and with some prom-
ising experimental studies that have proved a
measurable  antitumor  immune  response
against  neuroblastoma.9,10 In  the  allogeneic
setting,  the  biological  targets  of  the  graft-
versus-tumor (GvT) effect are unknown and it
has been believed that the GvT effect is ques-
tionable  in  neuroblastoma.  Although  primary
neuroblastoma  cells  may  lack  high-level  ex-
pression of MHC class 1 and class 2 antigens,
they should still be good target cells for a cel-
lular immune response given that there is up-
regulation of both classes of MHC molecules
after conventional therapy and after exposure
to proinflammatory cytokines. Minor histocom-
patibility antigen (mHA) may also be a possible
target.11 In  2006,  the  Accreditation  Subcom-
mittee of the EBMT classified HSCT procedures
according to prevailing clinical practice in Eu-
rope and categorized allo-HSCT for high-risk
neuroblastoma as a clinical option (with sib-
ling  donor)  or  developmental  (with  well-
matched unrelated donor).12 Stating this back-
ground, the AIEOP Study Group for NB together
with the HSCT Study Group, started in 2007 the
experimental protocol called Reduced Intensity
Conditioning Regimen and Allogeneic Stem Cell
Transplantation from Related or Unrelated HLA
Identical Donor in High Risk Neuroblastoma.13
Based on this experience, in the following year
has been open to the enrollment another pro-
tocol  named  Reduced  Intensity  Conditioning
Regimen and Allogeneic Stem Cell Transplanta-
tion from Related Or Unrelated HLA Identical
Donor in Soft Tissue Sarcoma and Ewing Sar-
coma.14 Both of the studies are still open and
enrolling  patients.  The  results  of  these  two
novel approaches need a longer follow-up to be
completely evaluated but the preliminary obser-
vations  can  be  resumed  as  following:  im-
munotherapeutical  approach  is  feasible,  not
toxic  with  an  acceptable  transplant-related
mortality (TRM) and compared with HLA mis-
matched  donors  allogeneic  HSCT  from  HLA-
matched sibling donors has shown no signifi-
cant evidence of improving outcome following
allografting. With the goal to obtain a rapidly
available donor in any moment of the disease
natural history, has been elaborated an experi-
mental design for RIC HSCT in pediatric solid
tumors using also full haplotype mismatched
donors. The principles of this setting remain
the same of the experience with haematolog-
ical malignancies:15 the megadose of CD34+
purified stem cell (SC) (>10x10
6 cells/kg) over-
comes the barrier of residul anti-donor CTL-p
cytotoxic T cell preventig rejection and allows
rapid engraftment with a consequent low TRM
and  the  extensive  T-cell  depletion  (<5x10
4
CD3+  T-cell)  dramatically  reduces  the  inci-
dence of GvHD so that no immunosoppressive
therapy is to be administered after HSCT. To in-
vestigate the potential role of NK-alloreactivity
cell against solid tumors is one of the most in-
triguing  biological  objectives  of  this  experi-
mental design. The source of SC is an immuno-
magnetic-based purification of CD 34+ cell ob-
tained by mobilized peripheral blood mononu-
cleated cells. The donor selection is based on
the KIR-KIR-ligand mismatch alloreactivity of
NK cells. The T-cell quote cointained in the in-
oculum of purified CD34+ has not to overcome
the threshold of 5x104/kg of weigh of the recip-
ient. The RIC is a fludarabine-based regimen
with the use anti-thymocyte immunoglobulin
(ATG):  melphalan  2x70  mg/sqm,  fludarabine
4x40 mg/sqm, thiothepa 2x5 mg/kg, ATG 4x2.5
mg/kg. Since 2009, 4 patients has been enrolled
in the study (2NB, 1 ESFT and 1 Wilms’ tumor).
The state of the disease before HSCT was par-
tial response (<50%) for all the patients. The
donors have been mothers in 
3⁄4 cases and fa-
ther in one case. The median of CD 34+ cells/kg
infused has been 19 (15-24) x106. The median
of  T-cells  into  the  inocolum  has  been  4.51
(1.44-7.1)  x104.  The  median  Follow-Up  time
has been 4 months.3-7 The median time of take
has  been  10  days  for  polimorphonucleated
cells8-12 and 10 days for platelets respectively.9-
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12 Complete  donor  chimerism  has  been  ob-
tained in all of the patients at day +30. The me-
dian of absolute number of circulating NK-cells
has  been  as  following:  at  day  +15,  0.5
cells/mm3, at day + 30, 8.5 cells/mm3, at day
+60, 40.6 cells/mm3, at day +90, 75.1 cells/mm3.
No add-back of stimulated freshly NK cells has
been infused after the HSCT. No re-activation
of CMV or EBV has been reported. About the
outcome: 2 patients ere alive in complete re-
mission, 1 patient has died for progression of
the disease (stage IV n-Myc amplified refrac-
tory NB in PR before HSCT) and 1 pts died of
lung IFI >100 days afer HSCT. From these pre-
liminary results we can resume that: the Fluda-
based RIC preparative regimen was associated
with a low grade of organ and hematological
toxicity (no grade III-IV OMS toxicity was evi-
denced) in such heavly treated population, ex-
tensively  T-cell  ex  vivo depletion  (average
4.51x10
4 CD3+ cells infused) allowed no GVHD
in  our  cases,  in  an  half  of  the  patients  the
HSCT procedure allowed to obtain a complete
remission of the disease. To validate these re-
sults a longer follow-up time and a larger cohort
of patients is certainly needed. In conclusion,
early studies of HLA mismatched-HSCT in chil-
dren with high-risk solid tumors suggest that
this is a feasible approach that may improve
the outcome in this deadly disease. Although
there are a limited number of cases, knowledge
of  these  data  provides  a  basis  for  decision-
making in future studies design. Not only in
the subset of patients for whom dose escalation
strategies  appear  to  be  failing  but  also  for
newly diagnosed patients, there is a need to de-
velop newer strategies based on innovative, im-
munobiological concepts.
References
1. Pession A, Dama E, Rondelli R, et al. Sur-
vival of children with cancer in Italy, 1989-
98. A report from the hospital based reg-
istry of the Italian Association of Paedi-
atric Haematology and Oncology (AIEOP).
Eur J Cancer 2008;44:1282-9.
2. De Bernardi B, Nicolas B, Boni L, et al.
Disseminated neuroblastoma in children
older than one year at diagnosis: compa-
rable results with three consecutive high-
dose protocols adopted by the Italian Co-
Operative Group for Neuroblastoma. J Clin
Oncol 2003;21:1592-601.
3. Bisogno G, Ferrari A, Prete A, et al. Se-
quential high-dose chemotherapy for chil-
dren with metastatic rhabdomyosarcoma.
Eur J Cancer 2009;45:3035-41.
4. Rosito  P,  Mancini  AF,  Rondelli  R,  et  al.
Italian  Cooperative  Study  for  the  treat-
ment of children and young adults with lo-
calized Ewing sarcoma of bone: a prelimi-
nary  report  of  6  years  of  experience.
Cancer 1999;86:421-8.
5. Sari N, To˘ gral G, Cetinda˘ g MF, et al. Treat-
ment results of the Ewing sarcoma of bone
and  prognostic  factors.  Pediatr  Blood
Cancer 2010;54:19-24.
6. Balamuth  NJ,  Womer  RB.  Ewing’s  sar-
coma. Lancet Oncol 2010;11:184-92.
7. Yalçin B, Kremer LC, Caron HN, van Dalen
EC. High-dose chemotherapy and autologous
haematopoietic stem cell rescue for children
with  high-risk  neuroblastoma.  Cochrane
Database Syst Rev 2010;CD006301.
8. Pession A, Prete A, Locatelli F, et al. Phase
I  study  of  high-dose  thiotepa  with
busulfan, etoposide, and autologous stem
cell support in children with disseminated
solid  tumors.  Med  Pediatr  Oncol  1999;
33:450-4.
9. Valteau-Couanet  D,  Leboulaire  C,  Main-
cent K, et al. Dendritic cells for NK/LAK ac-
tivation:  rationale  for  multicellular  im-
munotherapy  in  neuroblastoma  patients.
Blood 2002;100:2554-61.
10. Rousseau RF, Haight AE, Hirschmann-Jax
C, et al. Local and systemic effects of an al-
logeneic  tumor  cell  vaccine  combining
transgenic human lymphotactin with in-
terleukin-2 in patients with advanced or
refractory neuroblastoma. Blood 2003;101:
1718-26.
11. Barrett D, Fish JD, Grupp SA. Autologous
and allogeneic cellular therapies for high-
risk  pediatric  solid  tumors.  Pediatr  Clin
North Am 2010;57:47-66.
12. Ljungman P, Urbano-Ispizua A, Cavazzana-
Calvo M, et al. Allogeneic and autologous
transplantation  for  haematological  dis-
eases, solid tumours and immune disor-
ders: definitions and current practice in
Europe.  Bone  Marrow  Transplant  2006;
37:439-49.
13. Prete A, Rondelli R, Locatelli F, et al. Allo-
geneic stem cell transplantation from hla-
identical donor in high-risk sarcoma. Bone
Marrow Transplant 2010;45:174.
14. Fagioli F, Prete A, Rondelli R, et al. Allo-
geneic stem cell transplantation from HLA
identical  donor  in  high-risk  sarcoma.  J
Clin Oncol 2010:28:9561.
15. Aversa F, Terenzi A, Tabilio A, et al. Full hap-
lotype-mismatched hematopoietic stem-cell
transplantation: a phase II study in patients
with acute leukemia at high risk of relapse.
J Clin Oncol 2005;23:3447-54.
Article